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ABSTRACT
Nasal administration has been proposed as a potential approach for the delivery of drugs to the cen-
tral nervous system. Ribavirin (RBV), an antiviral drug potentially useful to treat viral infections both in
humans and animals, has been previously demonstrated to attain several brain compartments after
nasal administration. Here, a powder formulation in the form of agglomerates comprising micronized
RBV and spray-dried microparticles containing excipients with potential absorption enhancing proper-
ties, i.e. mannitol, chitosan, and a-cyclodextrin, was developed for nasal insufflation. The agglomerates
were characterized for particle size, agglomeration yield, and ex vivo RBV permeation across rabbit
nasal mucosa as well as delivery from an animal dry powder insufflator device. Interestingly, perme-
ation enhancers such as chitosan and mannitol showed a lower amount of RBV permeating across the
excised nasal tissue, whereas a-cyclodextrin proved to outperform the other formulations and to match
the highly soluble micronized RBV powder taken as a reference. In vivo nasal administration to rats of
the agglomerates containing a-cyclodextrin showed an overall higher accumulation of RBV in all the
brain compartments analyzed as compared with the micronized RBV administered as such without
excipient microparticles. Hence, powder agglomerates are a valuable approach to obtain a nasal formu-
lation potentially attaining nose-to-brain delivery of drugs with minimal processing of the APIs and
improvement of the technological and biopharmaceutical properties of micronized API and excipients,
as they combine optimal flow properties for handling and dosing, suitable particle size for nasal depos-
ition, high surface area for drug dissolution, and penetration enhancing properties from excipients
such as cyclodextrins.
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Introduction
Viral diseases are considered a major global threat to human
and veterinary public health (Howard & Fletcher, 2012). As
emerging viral infections, they frequently originate from an
animal host and many involve the central nervous system
(CNS) causing encephalitis, meningitis and consequent acute
flaccid paralysis/poliomyelitis, as in the case of West Nile
Virus and others (Tyler, 2009). Also measles was recently
added to the NIAID's list of emerging virus infections and
may cause CNS complications soon after infection (Garg,
2008) or few years later, as a result of viral persistence that
leads to subacute sclerosing panencephalitis (Mahajan et al.,
2014). The treatment and control of viral infections in the
CNS is a therapeutic challenge because of the blood–brain
barrier (BBB) and the blood–cerebrospinal fluid barrier.
The extensive tight junctions between the endothelial cells
of brain capillaries, the lack of paracellular transport, and lim-
ited pinocytosis, together with active efflux transporters,
result in low cerebrospinal fluid-plasma ratios for most of the
antiviral drugs (Wong et al., 2012; Comfort et al., 2015).
The nasal route has been extensively studied for the
administration of drugs directly to the CNS (Landis et al.,
2012). In fact, this route exploits the olfactory region and the
trigeminal nerve pathway to enable drugs’ entry into the
CNS bypassing the BBB (Hanson & Frey, 2008). This delivery
approach was explored for the administration of ribavirin
(RBV), in view of an innovative treatment of the encephalitis
associated with canine distemper virus, a major veterinary
infection that could serve as a proof of concept of the
approach. This virus belongs to the Morbillivirus genus as the
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measles virus and primarily infects dogs (Elia et al., 2008; Dal
Pozzo et al., 2010). RBV is a synthetic guanosine antiviral ana-
log. It has a broad-spectrum antiviral activity, being clinically
effective against several viruses and successfully tested in
vitro against several RNA and DNA virus infections (Beaucourt
& Vignuzzi, 2014). The drug is currently marketed in oral dos-
age forms; however, it has been clinically administered as
pulmonary aerosol in the treatment of respiratory syncytial
virus (Li et al., 2012) and for the therapy of measles pneumo-
nia (Safdar et al., 2009) as well as intravenously and intraven-
tricularly for subacute sclerosing panencephalitis (Tomoda
et al., 2003; Garg, 2008). However, the latter two approaches
are plagued by adverse effects and exploit a highly invasive,
risky, and infection-prone administration route, remarkably
fostering the development of an alternative delivery route
such as nasal administration. Our group showed that measur-
able brain concentrations of RBV can be obtained in rats
after intranasal administration of a RBV aqueous solution. In
particular, it was evidenced that 20min after nasal adminis-
tration, RBV was highly concentrated in the olfactory bulb
and in other brain structures after nasal administration
(Colombo et al., 2011).
Currently, despite liquid dosage forms prevail in nasal
drug delivery, a powder formulation would be preferable
from a chemical and biopharmaceutical perspective. In fact,
liquids are plagued by limited residence time in the nasal
cavity, chemical and microbiological stability issues, and limit
the deliverable dose due to the drug solubility and the max-
imal concentration attainable in aqueous vehicles (Buttini
et al., 2012). In this regard, the superiority of nasal powders
has been demonstrated in vitro (Colombo et al., 2016; Pozzoli
et al., 2017), in animal studies (Balducci et al., 2013b), and in
clinical trials (Fransen et al., 2009).
In light of this, the aim of this work was to formulate RBV
as a nasal powder with appropriate physico-chemical proper-
ties for nasal delivery and containing a functional excipient
that could act as penetration enhancer to improve the nose-
to-brain delivery of the antiviral drug.
Micronized RBV appears as a promising starting material,
with rapid dissolution assured by the high surface area of
the micron-sized crystals. However, its technological proper-
ties are poor. In particular, bad powder flow and high cohe-
siveness, typical of micronized powders, may hinder
handling, dosing, and powder aerosolization for intranasal
deposition.
In order to improve the technological properties of the
micronized drug powder, it was previously demonstrated
that lecithin-containing spray-dried microparticles could be
used to form agglomerates by simple mechanical processes
(Sacchetti et al., 2002). These soft agglomerates were of a
size sufficiently large to allow for precise handling and dos-
ing, but weak enough to break upon insufflation and rapidly
dissolve in the presence of aqueous secretions (Russo et al.,
2004).
Here, agglomerates were prepared by mixing the RBV raw
material with excipient microparticles obtained by spray dry-
ing. These excipient microparticles were composed of lecithin
associated with a hydrophilic component among mannitol,
chitosan, or a-cyclodextrin. Mannitol has been demonstrated
to alter mucosal permeability by osmotic effect (Hirsh, 2002;
Farkas et al., 2005). Chitosan is a cationic polysaccharide with
bioadhesive and permeation enhancing properties through
transient opening of tight junctions (Caramella et al., 2010).
Cyclodextrins are well known for their nasal bioavailability
enhancement, by various mechanisms including deprival of
cholesterol from the mucosal membrane and improved para-
cellular drug transport (Rassu et al., 2015; Kulkarni & Avachat,
2017). Hence, RBV microcrystals were agglomerated with
microparticulate excipients with potential permeation
enhancing properties.
RBV, excipient microparticles, and agglomerates were
characterized in vitro with respect to size distribution, morph-
ology, and technological properties. Ex vivo transport experi-
ments across rabbit nasal mucosa were conducted in order
to compare RBV agglomerates with the RBV aqueous solution
and RBV raw material, both used as reference. Finally, the
agglomerate formulation that showed the best performance
in vitro was administered intranasally to rats.
Materials and methods
Materials
Ribavirin raw material (batch #001-RIB-0908) was kindly
donated by Euticals S.p.A. (Lodi, MI, Italy). The micronized
powder was demonstrated to be exclusively the crystalline
polymorph R-I by X-ray diffraction (data not shown) and DSC
(Tm¼180 C), probably as a result of the milling process as
reported by Vasa (Vasa & Wildfong, 2017). RBV analytical
standard was purchased from Sigma Chemical Company (St.
Louis, MO). The internal standard (IS) 13C5RBV was obtained
from Campro Scientific GmbH (Berlin, Germany). Mannitol
was a kind gift of Lisapharma S.p.A. (Erba, Italy). Chitosan
(ChitoClearVR , batch TM1874) was supplied by Primex
(Siglufjordur, Iceland). The oligosaccharide a-cyclodextrin
(a–CD, A.C.E.F. S.p.A., Fiorenzuola d’Arda, Italy). Lecithin
(LIPOID S45) was obtained from Lipoid GmBH (Ludwigshafen,
Germany). Degassed ultrapure water (Purelab Flex, ELGA-
Veolia LabWater, Zoppola, Italy) was used in all experiments.
All other reagents and solvents were of analytical grade.
Methods
RBV chromatographic analysis
HPLC method for in vitro and ex vivo experiments.
The RBV concentration in samples from in vitro experiments
was quantified by a reverse phase-HPLC method previously
described (Colombo et al., 2011). Briefly, RBV was quantified
using a Synergi Polar-RP 4 mm, 150mm 4.6mm
(Phenomenex, Castelmaggiore, Italy). Separation was obtained
by isocratic elution carried out with a 20mM (NH4)2HPO4 solu-
tion in water (pH 7.5) as mobile phase. The analyses were car-
ried out at room temperature, flow rate 0.8ml/min and
detection wavelength 225 nm. The injection volume was 20 ll.
In these conditions, the retention time of ribavirin was around
3.7min. The method was linear (R2¼ 0.999) in the concentra-
tion range between 1.28 and 410mg/ml, RSD (n¼ 6) was
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0.34%, limit of quantitation (LOQ) and limit of detection (LOD)
were 0.056 and 0.017 mg/ml, respectively, and theoretical
plates were 4553± 339.
LC-MS/MS method for in vivo experiments. For the in vivo
studies, RBV concentration in brain and blood extracts was
determined according to a method already published (Zironi
et al. 2011). Briefly, after the addition of 13C5RBV (IS), RBV
was extracted from samples with ammonium acetate buffer.
The analyses were conducted on an Alliance 2695
Separations Module coupled with triple quadrupole mass
spectrometer Quattro Premiere XE, (Waters Corporation,
Milford, MA). Chromatographic separation was performed on
a Waters Atlantis T3 column (3 lm, 2.1mm 150mm). All the
analyses were conducted in positive electrospray ionization
mode (ESIþ) using selected reaction monitoring (SRM);
the transitions monitored were RBV m/z 245!113, 13C5RBV
m/z 250!113. The LOQ was 5 ng/g and the linearity
(R2>0.99) was demonstrated over a concentration range of
5–1000 ng/g.
Spray-dried excipient microparticle manufacturing. The
excipient microparticles were constituted by two components
blended at mass ratio 15:85. The first component was always
soybean lecithin, that confers adhesive properties, whereas
the second one was a hydrophilic excipient with functional
properties, namely mannitol, chitosan, or a–cyclodextrin
(a–CD). The corresponding excipient microparticles were
coded M1, M2, and M3.
The excipient microparticles were manufactured by means
of a B-191 Mini Spray Dryer (B€uchi, Flawil, Switzerland) under
the following operating conditions: airflow 600 l/h and
aspiration 35 m3/h. The feeding solution was prepared by
separately solubilizing lecithin in ethanol and mannitol or
a–CD in ultrapure water (Purelab Flex, ELGA-Veolia LabWater,
Windsor Court, UK). Chitosan was dissolved in a 1% w/w lac-
tic acid solution (pH 2.4). The lecithin solution was then
added to the aqueous solution at volume ratio 1:10 under
magnetic stirring. The total solid concentration in the feed
solution was 2% w/v. The liquid feed was sprayed at 4ml/
min.
The inlet and the outlet temperatures of the air for the
drying process were 130 and 68 C for M1, 120 and 52 C for
M2 and 105 and 54 C for M3 microparticles preparation.
Percentage process yields were calculated as the ratio
between the weight of the powder recovered in the collector
at the end of the process and the amounts of materials
weighed for the preparation of the feeding solution.
Microparticle agglomeration. Before the agglomeration pro-
cess, the crystalline powder of micronized ribavirin (mRBV)
was blended with the spray-dried excipient microparticles at
1:1 mass ratio. One gram of each powder was weighed inside
a pillbox of 30ml capacity with two glass spheres (7.83mm
in diameter) and then mixed in a TurbulaVR blender (WAB,
Muttenz, Switzerland) for 10min. Then, as the mixture par-
tially adhered to the container’s wall, it was gently scraped
off with a spatula and the powder further mixed for 10min.
Blend homogeneity with respect to drug content was
assessed by HPLC by dissolving 10mg of the blend in mobile
phase.
For agglomeration, 2 g of the blend were placed on top
of a 2-sieve nest (10 cm diameter sieves, Endecotts Ltd,
London, UK; nominal aperture 500 and 300 mm, respectively)
on a laboratory sieve shaker (Vibratory Sieve Shaker, RetschVR ,
Haan, Germany) (Russo et al., 2006; Balducci et al., 2013a).
The system was vibrated for 5min at an amplitude of 4/5.
The agglomerates retained on the 300 mm sieve were col-
lected, weighed to calculate the percentage agglomeration
yield (ratio between the weight of the agglomerates on the
sieve and the amounts of materials processed), and stored in
tightly closed containers for further studies. Reprocessing of
non-agglomerated powder was repeated five times. The drug
loading of the agglomerates was evaluated by HPLC by dir-
ectly dissolving 10mg of the agglomerates in mobile phase.
Microparticle and agglomerate characterization
Scanning electron microscopy analysis. The morphology of
RBV raw material, spray-dried excipient microparticles and
agglomerates was examined by Field Emission – Scanning
Electron Microscopy (FE-SEM), using a Zeiss SUPRA 40 micro-
scope (Zeiss, Oberkochen, Germany). The powder samples
were fixed onto high-purity aluminum pin stubs using dou-
ble-sided tape, with the exception of the agglomerates which
were dipped in silver glue (Conductive Silver Paint, Agar
Scientific, Stansted, UK), as it was not possible to stick them
onto the bioadhesive tape without breaking them. This paint
formed a thin highly conductive film on the agglomerate’s
surface. In all cases, the magnifications selected ranged
between 250 and 5000 to appreciate both the whole par-
ticle and its surface detail.
Water content analysis. Residual water content in RBV raw
material and in excipients microparticles was determined by
Karl-Fisher titration (TitroMatic KF 1 S, Crison, Barcelona,
Spain). Samples were analyzed in triplicate using around
100mg of powder and using sodium tartrate tetrahydrate as
standard.
Particle and agglomerate size distribution and flowability.
Size distribution analysis of mRBV raw material and spray-
dried excipient microparticles was carried out by a wet
method using a SpraytecVR laser diffractometer (Malvern
Instruments, Malvern, UK). Approximately, 10mg of excipient
microparticles were suspended in acetone and measured
using a particle and dispersant refraction index of 1.000 and
1.3588, respectively. The analysis was conducted in triplicate
for each batch.
The agglomerates’ size distribution was determined by
optical microscopy (Citoval 2, Alessandrini, Modena, Italy)
equipped with a digital camera (CCD-1, JVC, Tokyo, Japan).
For the observation, agglomerates were gently spread under
the objective in order to obtain an evenly spaced distribu-
tion. Images of the agglomerates were acquired and ana-
lyzed using the open source image processing package FiJi
(Schindelin et al., 2012) to measure the projected area
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diameter of at least 800 agglomerates per batch. Finally, the
cumulative percentile of the powders in the range between
300mm and 1000mm in a frequency distribution with 50 mm
intervals was calculated using the Statplus software
(AlaystSoft, Walnut, CA).
Powder flowability was evaluated by measuring the appar-
ent volumes of micronized RBV and AM3 agglomerates
according to the relevant Ph. Eur. chapter (2.9.36. Powder
Flow) (SVM 122, Erweka, Heusenstamm, Germany). The meas-
ured bulk and tapped volume values were used to calculate
the powder Compressibility (or Carr) Index (CI) according
to the following equation: Measurements were done in
triplicate.
CI ¼ VBulk  VTapped
VBulk
 100 (1)
The calculated CI value is a parameter characteristic of
powder flow properties with low values corresponding to a
powder with excellent flow and high values to a powder
with poor flow properties.
Ex vivo transport experiments across rabbit nasal
mucosa. The ex vivo RBV transport from the agglomerates
was investigated using vertical Franz-type diffusion cells
(0.58 cm2 area) and rabbit nasal mucosa as barrier according
to Bortolotti and colleagues (Bortolotti et al., 2009). Briefly,
on the day of the experiment rabbit heads were collected
from a local slaughterhouse (Pola, Finale Emilia, Italy) to dis-
sect the epithelium specimens from the nasal septum. The
relatively small size of rabbit nasal cavity does not allow to
separate the olfactory from the respiratory region. The
excised tissue was immediately inserted between the cell’s
donor and receptor compartments with the mucosal side fac-
ing the donor compartment. The two compartments were
tightly clamped. The receptor compartment was filled with
phosphate buffered saline (PBS) pH 7.4 (4ml) and maintained
under stirring at 37 C. Before adding the powder formula-
tion, 200 ml of PBS was added to the donor to wet the
mucosa. An amount of agglomerates equivalent to 5mg of
ribavirin or 0.5ml of a ribavirin solution in water (0.1mg/ml)
was loaded into the donor compartment.
At predetermined time points, 0.4ml of receptor solution
was withdrawn and the receptor compartment refilled with
an equivalent volume of fresh PBS. At the end of the experi-
ment, the residual formulation on the membrane was quanti-
tatively recovered by rinsing the donor compartment with
PBS. All samples were analyzed by HPLC. The experiments
were conducted in triplicate for each formulation.
Ex vivo powder insufflation with a dry powder insuffla-
tion device for small animals. A preliminary assessment of
powder behavior during insufflation was carried out using a
colored drug-free powder. In particular, the area of powder
deposition on the nasal mucosa of a rat was investigated.
The M3 spray-dried excipient microparticles were mixed with
a methylene blue powder (85:15). The PennCenturyTM Dry
Powder InsufflatorTM – Model DP-4 (PennCentury Inc,
Wyndmoor, PA) was used, which is designed to produce a
puff of fine powder. The device was loaded with 3mg of this
blend and the powder insufflated into the nostril using a rat
head. The head had been kept in the refrigerator for future
use, deriving from an animal previously sacrificed for other
purposes.
Intranasal administration of RBV
Animal care. Male pathogen-free Sprague–Dawley rats
(HarlanVR , Udine, Italy) weighing 125–150 g were used in
this study. Animals were housed in standard conditions at
22 C with 12-h light/dark cycle and received a standard
pellet diet (4RF21, Mucedola, Settimo Milanese, Italy) with
water available ad libitum. All animal experiments described
here were carried out according to the European
Community Council Directive of November 24th, 1986 (86/
609/EEC) and approved by intramural committee and the
Ministero della Salute (prot. 34613-X/10) in compliance
with the guidelines published in Guide for the Care and
Use of Laboratory Animals by the Italian National Research
Council.
In vivo RBV agglomerate administration. The conditions
for intranasal administration (including time-point for sacri-
fice) and CNS dissection for RBV quantification were
described and optimized in the previous work by Colombo
et al. (2011). All in vivo treatments were performed in anes-
thetized rats. Surgical anesthesia was induced by intraperito-
neal injection of ketamine (100mg/kg). Depth of anesthesia
was assessed by monitoring the loss of the hind limb with-
drawal reflex after pinch stimulation of the foot and the loss
of eyelids reflex. Core temperature was maintained at 37 C
using a heating pad. Briefly, two groups of rats (n¼ 6 per
group) received intranasally RBV agglomerates containing
a-cyclodextrin (AM3) or micronized RBV as reference. In both
cases, a 1mg total dose of RBV was administered unilaterally
to the left nostril with the animal lying horizontally on the
right side.
RBV was administered inserting the tip of the DP-4Dry
Powder InsufflatorTM device in the selected nostril of the rat.
To reach the requested dose, 2–3mg of the powder was
manually filled into the device’s holding chamber immedi-
ately before the administration. The amount of RBV delivered
was calculated based on the chamber’s weight difference
before and after use.
Animals were sacrificed 20min after administration of the
powder, to collect plasma and the brain compartments of
interest, i.e. olfactory bulb, cortex (anterior and posterior),
basal ganglia, and hippocampus. Sample collection and proc-
essing were according to conditions reported by Colombo
et al. (2011). After freezing in liquid nitrogen, samples were
stored at 80 C until analysis.
Statistical analysis
The overall data obtained from the in vivo experiments were
analyzed using an unpaired two-tailed Student’s t-test (Excel
Software, Microsoft Corp., Redmond, WA). Statistical signifi-
cance was accepted at p< .05.
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Results
The first part of the work attempted to formulate RBV as a
powder for nasal insufflation focusing on the production of
microparticles containing the antiviral drug along with the
excipients selected. However, it was soon found that spray
drying of RBV led to poor yields and unacceptable drug loss
in the process due to drug accumulated as a sticky layer on
the equipment glassware (data not shown). This was deemed
a consequence of the substance’s known hygroscopic behav-
ior (Lachenmann et al., 1990).
The alternative decision, then, was to use the pure
micronized RBV crystals without processing and formulate
them with spray-dried microparticles containing excipients
able to favor the nasal administration and nose-to-brain
absorption of the hydrophilic drug. RBV microcrystals then,
together with microparticulate excipients with permeation
enhancing properties, could be used to obtain a dosage
form able to maintain the rapid dissolution characteristics of
micronized crystals, improve the poor flowability of the
micronized powder and exploit the functional properties of
the excipients, which might facilitate the transport of the
antiviral across the olfactory mucosa.
SEM images of RBV raw material and the spray-dried
excipient powders have been included in Appendix provided
as Supplemental File (Figure A1). The raw material presented
a typical crystalline appearance with elongated, columnar or
tabular shape characterized by a quite broad size distribu-
tion. In contrast, the spray-dried microparticles were spherical
and homogenous micron-sized structures. In all three excipi-
ent particles, two populations of microparticles were identi-
fied, one population of larger particles with size around
10 mm and a second main population of smaller particles of
few microns.
The excipients’ powder morphology was quite different.
Mannitol–lecithin microparticles (M1) appeared as hollow
shells with numerous evident cracks and fractures.
Chitosan/lecithin microparticles appeared more regular than
M1 and somehow denser. Finally, in the case of M3 pow-
der, where a-cyclodextrin was employed along with lecithin,
all particles were shriveled, suggesting the collapse of a
dense shell over a hollow core during the drying process.
Table A1 lists the production yield, particle size, and
residual water content of the spray-dried microparticles and
RBV raw material are provided also in the Appendix (Table
A1 in Supplemental File).
The spray drying yields were around 50%. Particle sizing
data confirmed that RBV was a micronized powder with a
Dv,50 volume diameter close to 10 mm and relatively broad
size distribution (span value 2.36). In contrast, excipient
microparticles presented a narrower size distribution (span
value 2.00) with a Dv,50 value between 6 and 7 mm.
Microparticles containing chitosan and a-cyclodextrin had a
relatively high residual water content as a result possibly of
the lower inlet temperature in the spray drying process and
of the hydrophilic nature of the polysaccharide excipients
used in association with lecithin. On the contrary, M1 powder
had a significantly lower residual water content reflecting the
low hygroscopic behavior of its polyol component.
Agglomerates were prepared from a 1:1 mass ratio blend
of the micronized RBV powder (mRBV) with each one of the
excipient microparticles by vibration upon a sieve stack.
Figure 1 shows the agglomerates obtained using the three
excipient microparticles formulation. Agglomerates produced
with mannitol/lecithin microparticles (AM1, Figure 1(A)) and
chitosan/lecithin microparticles (AM2, Figure 1(B)) appear
more spherical and densely packed. The agglomerates
obtained with a-cyclodextrin/lecithin microparticles (AM3,
Figure 1(C)) are bristly and less spherical. The observation of
the agglomerates’ surface at higher magnification evidenced
a homogenous distribution of the microparticles and micron-
ized drug crystals.
Cumulative particle size distribution of the agglomerates
obtained by optical microscopy, as well as the agglomeration
yield, RBV content of the blend before agglomeration and
RBV content of the agglomerates are included in the
Appendix provided as Supplemental File.
The agglomerates obtained with mannitol/lecithin micro-
particles AM1 were those presenting a larger size distribution
with 50% of the agglomerates between 350 and 400mm. The
same agglomerates showed also a lower percentage of par-
ticles below 300mm. Since agglomerates were formed on a
sieve with nominal aperture of 300 mm, it is expected that
the presence of particles below this value correlates with the
tendency of agglomerates to break or shed fragments. This
suggests that AM1 agglomerates were likely stronger in
terms of mechanical resistance, as smaller quantities of frag-
ments or non-agglomerated powder were evidenced. The
size distribution of agglomerates obtained with chitosan/leci-
thin (AM2) and a-cyclodextrin/lecithin microparticles (AM3)
was superimposable, with half of the particles with a diam-
eter around 350 mm.
The yield of agglomeration for the three mixtures was in
the range between 70 and 90%, with the agglomeration effi-
ciency of AM3 significantly higher than the one obtained for
AM1 (p< .01). Furthermore, despite the differences observed
in the macroscopic features of the agglomerates, their drug
content was very close to the theoretical 50% according to
the 1:1 ratio by weight of the initial mixture (see Table 1).
In order to evaluate the biopharmaceutical characteristics
of the agglomerates, the permeation of the antiviral drug ex
vivo across rabbit nasal mucosa from the agglomerates was
compared with that obtained from the micronized raw
material as such (Figure 2).
The permeation of the antiviral drug was found to be rela-
tively low in percentage from the agglomerates produced
using chitosan/lecithin microparticles. Agglomerates pro-
duced using mannitol/lecithin microparticles showed a per-
meation similar to RBV microcrystals only until the first time
point, then the total permeation after 4 hours was just below
60% of the loaded drug, thus significantly lower than the
80% obtained with the drug microcrystals. The micronized
crystals and the agglomerates produced with a-cyclodextrin/
lecithin microparticles showed instead a higher drug perme-
ation leading to an almost complete diffusion across the bio-
logical barrier within the time of the experiment. In
particular, the agglomerates containing a-cyclodextrin pro-
vided a total permeation after 4 h above 95%. The different
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results observed were explained considering that despite all
the excipients selected for the agglomerates had the poten-
tial to enhance the permeation of a hydrophilic drug, their
presence could have affected the drug dissolution. The
slower the dissolution, the lower the drug concentration at
the mucosal surface and slower the diffusion. Drug dissol-
ution profiles were determined using the same Franz-type
diffusion cells and a porous cellulose acetate membrane as
barrier, showing faster dissolution for RBV microcrystals and
for agglomerates obtained with a-cyclodextrin/lecithin micro-
particles (AM3), followed by those obtained with mannitol/
lecithin microparticles (AM1) and chitosan/lecithin
Figure 1. SEM images depicting the morphology of ribavirin-excipient agglomerates obtained with (A–A’) mannitol/lecithin microparticles (AM1); (B–B’) chitosan/
lecithin microparticles (AM2), and (C–C’) a-cyclodextrin/lecithin microparticles (AM3) at 250 and 1200 magnification.
Table 1. Yield of agglomeration (%), ribavirin content in the blends before
agglomeration and in the final agglomerates produced (n¼ 3, average ± SD).
Blend 1:1
Agglomeration
Yield (%)
RBV Content
in Blend
(% w/w)
RBV Content in
Agglomerates
(% w/w)
AM1 70.4 ± 3.2 53.8 ± 2.5 50.0 ± 4.2
AM2 80.2 ± 8.4 50.6 ± 0.5 53.7 ± 3.0
AM3 91.0 ± 5.2 47.9 ± 1.2 47.9 ± 1.6
Significantly different (p< .01) from agglomeration yield obtained for AM1.
Figure 2. Ribavirin permeated (% of loaded dose) across rabbit nasal mucosal
tissue from lRBV (), and agglomerates obtained from micronized ribavirin
crystals with mannitol/lecithin microparticles AM1 (), chitosan/lecithin micro-
particles AM2 () or a-cyclodextrin/lecithin microparticles AM3 () (n¼ 3,
average ± SD).
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microparticles (AM2) (see Figure A3 in the Appendix in
Supplemental File).
In light of the results of the ex vivo permeation experi-
ment, the agglomerates containing the micronized RBV crys-
tals with a-cyclodextrin/lecithin microparticles were selected
for the in vivo study of RBV brain distribution after nasal
administration.
For the administration of the powders into the animal’s
nose, a dry powder insufflator available for the pulmonary
administration of powders to small animals was used. A pre-
liminary study ex vivo was carried out to determine the
device’s optimal positioning and evaluating powder depos-
ition in the rat nasal cavity. Figure 3 shows the device
(Figure 3.1), the positioning of its tip within the nostril of the
animal (Figure 3.2) and the distribution of the agglomerate
powder after insufflation (Figure 3.3 and 3.4). The agglomer-
ate powder loaded with a blue dye (black areas in Figure 3.3)
is marking the deeper section of the animal nasal cavity
where the olfactory and trigeminal innervation is present
(Dhuria, 2010). The preliminary experiment carried out here
was necessary to assess the distribution of the powder in the
nasal cavity and rule out the formation of a clog or lumps at
the site of insufflation.
The in vitro performance of the device when loaded with
the agglomerates and with the micronized RBV powder in
terms of air volume and number of actuations for insuffla-
tion, and percentage emitted powder is presented in Figure
3.5. As expected, mRBV was more difficult to aerosolize for
nasal insufflation. In fact, in the case of the micronized crys-
tals the device delivered less than 50% of the loaded amount
of powder either with high or low air volume setting. In con-
trast, agglomerates delivered a significantly higher amount of
powder in both conditions and only two actuations were suf-
ficient to deliver more than 75% of the loaded amount of
powder when the device was operated with the higher vol-
ume of air. The observed results can be related to the
improved flowability of the agglomerated powder compared
to the micronized RBV, as shown by the calculated Carr
indexes. In fact, CI values were 10 ± 3 for AM3 agglomerates
and 28 ± 1 for micronized RBV, corresponding to excellent
and poor flow characteristics according to the European
Pharmacopoeia scale of flowability.
Based on the device performance in vitro, for the in vivo
experiments it was decided to use the device in the follow-
ing conditions: 2ml air volume and not more than two insuf-
flations, in order to maximize the powder delivered without
stressing the animals. The exact amount delivered to each
animal was determined by accurately weighing the device
before and after the insufflation.
After the nasal administration of the formulations in vivo,
animals were sacrificed 20min post-treatment and the
amount of RBV accumulated in various brain regions quanti-
fied and normalized for the RBV dose actually administered.
RBV was quantified in the olfactory bulb and plasma, as well
as in basal ganglia, hippocampus, anterior and posterior cor-
tex and cerebellum. As shown in Figure 4, the highest
Figure 3. The panels are showing: (1) dry powder insufflator device; (2) tip insertion in the nose of an animal; (3) distribution in the nasal cavity of agglomerates
containing a blue marker, arrows indicate regions where the staining is more evident; (4) sketch showing the relative positioning of the trigeminal nerve (A), olfac-
tory nerves (B) and brain (C) in the animal head (reproduced with permission from Dhuria, 2010); (5) data related to in vitro powder delivery performance of the dry
powder insufflator device (n¼ 4, mean± SD); **significantly different from µRBV emitted powder, p< .01.
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concentrations of RBV were found in the olfactory bulb fol-
lowed by the posterior and anterior cortex and the other
brain regions. Plasma concentration was comparably low.
Agglomerates outperformed the micronized RBV powder pro-
ducing relatively elevated levels of antiviral in all the brain
regions analyzed. The differences between the two groups,
however, were not significant.
In order to evaluate the actual contribution of direct nose-
to-brain transport of RBV to the levels measured, the concen-
trations in the olfactory bulb obtained here by nasal adminis-
tration of the agglomerates were compared with those
obtained previously with the intravenous administration of
the same RBV dose per kg of body weight (Colombo et al.,
2011). This allowed for the calculation of the olfactory bulb
to plasma ratio (OB/plasma ratio) for both administration
routes (Figure 5). The OB/plasma ratio values supported the
direct nose-to-brain transport of the antiviral drug after nasal
administration of the RBV powder agglomerates.
The OB/plasma ratio value was significantly different (p< .05)
and nearly 6-fold as high in the case of the nasal administra-
tion of the agglomerates as for the intravenous
administration.
Discussion
Despite the field of nasal delivery is dominated by liquid
sprays, the use of dry powder formulations appears appeal-
ing for innovative products, in particular those designed for a
nose-to-brain delivery (Tiozzo Fasiolo et al., 2018). In fact, dry
powder formulations are providing several advantages over
liquids such as chemical stability, absence of preservatives,
higher unit dosages per administration, longer residence
time and contact with the nasal mucosa and eventually
improved bioavailability (Pozzoli et al., 2016). However, not
always the formulation of powders to be delivered to the
nose allows to combine together some of the most desirable
features. Ideally, particles should be sufficiently large to
obtain a good deposition in the nasal cavity, but at the same
time display a high surface area for fast dissolution.
Mucoadhesive or permeation enhancer excipients might be
included as well. One popular strategy is to use particle
engineering to achieve these goals. Spray drying is a tech-
nique that has elicited a lot of interest for pharmaceutical
particle engineering because of its versatility in term of
obtainable particle morphology, size, and density and possi-
bility to combine multiple components in the particle proc-
essing (Vehring, 2008). Spray-dried particles have been
proposed both for the delivery of drugs in form of dry pow-
ders both to the upper (Russo et al., 2006; Dalpiaz et al.,
2008; Chen et al., 2013) and the lower respiratory tract (Xu
et al., 2012; Chan et al., 2013; Belotti et al., 2015).
In the case of RBV, however, the impossibility of obtaining
spray-dried microparticles containing RBV at the desired high
drug content was evidenced, being the result of the hygro-
scopic behavior of the drug (Lachenmann et al., 1990).
Interestingly, it has been reported that handling of RBV poses
Figure 4. Ribavirin distribution in plasma and different brain compartments (OB: olfactory bulb; BG: basal ganglia; Hip: hippocampus; CTX Ant: anterior cortex; CTX
Post: posterior cortex; CRB: cerebellum) after the nasal administration of micronized ribavirin crystals (white bars) or agglomerates obtained with micronized riba-
virin and a-cyclodextrin/lecithin microparticles (AM3) (black bars) (n¼ 6, average ± SEM).
Figure 5. Olfactory bulb to plasma ratio (OB/plasma ratio) after nasal adminis-
tration of the same dose of ribavirin (1mg) by intravenous injection (grey bar)
or nasal administration of ribavirin agglomerates with a-cyclodextrin excipient
microparticles (black bar) (n¼ 6, average ± SEM). Data for the intravenous
administration are according to Colombo et al., 2011.
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considerable challenges as the raw material is subjected to
pharmaceutically relevant process-induced solid state
changes (Vasa & Wildfong, 2017). This has led to a different
exploitation of the particle engineering approach, here
applied to the manufacturing of functional excipients micro-
particles followed by the production of organized mixtures of
such microparticles with micronized crystals of the antiviral
drug in the form of spherical agglomerates.
In fact, due to the particle size distribution of the micron-
ized RBV powder and of the excipient microparticles, simple
powder blends of these two components are not suitable for
nasal delivery. In fact, both the technological (poor flow and
high cohesiveness) and biopharmaceutical properties (limited
deposition in the nasal cavity and inhalation into deeper air-
way sections for particles below 10 mm) of micronized pow-
ders make them not suitable for nasal administration.
However, the agglomeration of micron-sized powders, like
the present primary particles, is an elegant solution that
allows us to change the size distribution of the powder. This
improves flow and handling, while it retains other favorable
properties of the original powders, such as original solid
state, high surface area, and rapid dissolution. In addition,
the large agglomerates or their fragments can be deposited
in the nasal cavity by impaction and reduce particle inhal-
ation into the lungs (Russo et al., 2006; Balducci et al.,
2013b).
In terms of particle size distribution and shape, the spray-
dried excipients microparticles were similar to those obtained
previously by ours and other groups. The differences in par-
ticle structure (dense, hollow, shriveled) have been attributed
to the slightly different drying conditions applied, but mostly
to the behavior of the components during the drying pro-
cess, i.e. their preferential absorption on the particle surface
or diffusion away from the surface, as already described and
exploited to obtain low-density microparticles (Tsapis et al.,
2002; Belotti et al., 2014). Here, mannitol, a small molecule
with higher diffusion coefficient, led to full spheres, chitosan,
a large polymer, to shriveled particles, very similar to those
obtained for protein-based spray dried particles (Balducci
et al., 2014) and a-cyclodextrin, an oligosaccharide having
surface active properties, led to the production of hollow
microparticles. Those shape differences could be attributed
to the effect of molecular weight and solubility in the liquid
feed of the three selected excipients.
However, despite the different particle structures, the
agglomeration properties of the microparticles were not sub-
stantially different among the three compositions and this
was attributed to the lecithin presence at the same concen-
tration in all cases. All compositions, in fact, produced
agglomerates with satisfactory process yields. It is possible
that the excipient microparticles residual water content
played also a role in favoring the agglomeration process,
since M2 and M3 spray-dried particles producing agglomer-
ates with micronized RBV crystals with yields above 80%,
showed a significantly higher residual humidity compared to
M1 microparticles. The actual RBV content in the agglomer-
ates reflected the drug content determined for the
blend before agglomeration, indicating a homogenous
incorporation of the drug in the agglomerates with no drug
loss or enrichment caused by the agglomeration process.
However, differences became evident with respect to RBV
permeation ex vivo across rabbit nasal mucosa. RBV is a
highly hydrophilic and water-soluble molecule and conse-
quently its permeation across the biological barrier is
expected to occur relatively slowly (Costantino et al., 2007;
Illum, 2012). It was confirmed that the permeation occurred
at great extent when the drug was in the form of micronized
crystals, due to the intimate contact with the lining fluid of
the mucosa, the rapid dissolution and the concentration gra-
dient achieved, that was the highest possible (Buttini et al.,
2012; Tiozzo Fasiolo et al., 2018). Quite surprisingly, agglom-
erates containing chitosan/lecithin microparticles were those
that led to a significantly lower permeated amount compared
to the micronized RBV. Chitosan has been indicated as the
excipient of choice for nasal delivery because it acts as an
absorption promoter with a double mechanism of action: it
acts as a mucoadhesive agent due to electrostatic interac-
tions with mucus components, and as a permeability enhan-
cer, transiently loosening tight junctions of nasal epithelial
cells (Casettari et al., 2012). On the one hand, many authors
reported improvements in drug mucosal permeation as a
consequence of the inclusion of chitosan in solution (Illum
et al., 1996), powder blends (Illum et al., 2002; Chen et al.,
2010), inserts (Luppi et al., 2010), nanoparticles (Wang
et al., 2009; Barbieri et al., 2015), and microparticles (Gavini
et al., 2013). On the other hand, some other reports indicate
that those permeation enhancing properties were diminished
or not evidenced in the case of nanoparticulate formulations
(Dyer et al., 2002; Illum, 2007) or when the microparticulate
formulation showed controlled release of the drug (Dalpiaz
et al., 2008). In the present case, the observed lack of perme-
ation enhancement with RBV could be related to similar rea-
sons. In fact, chitosan provides a more remarkable effect on
the permeability of the mucosal tissue when it is in form of
molecular dispersion. It can be hypothesized that the chito-
san in the M2 microparticle composition did not dissolve rap-
idly when deposited on the mucosal surface. Moreover, this
slow dissolution may have passed through the hydration and
formation of a gel that eventually slowed down the dissol-
ution of the RBV as well, leading to a gradual release and
relatively slow diffusion. Indeed, Tanaka et al. (2017) recently
attributed the reduced nasal absorption of warfarin, a highly
soluble and highly permeable drug, from formulations con-
taining different types of hydroxypropylcellulose (HPC) to the
delayed dissolution and slow diffusion of the drug in the vis-
cous fluid created by the polymer.
Mannitol is a safe non-ionic highly water soluble pharma-
ceutical excipient that has been recently used as hyperos-
motic agent in the treatment of chronic obstructive
pulmonary diseases, such as cystic fibrosis and bronchiectasis
(Hirsh, 2002; Young et al., 2014). The same hyperosmotic
effect is considered to improve paracellular transport of
hydrophilic drugs in epithelia and endothelia, suggesting a
mannitol-induced tight junction opening that has been used
also to induce disruption of the BBB (Deli, 2009). The perme-
ation of RBV across rabbit nasal mucosa from agglomerates
containing mannitol and lecithin also failed to outperform
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the micronized RBV crystals. In this case, the mannitol pre-
sent in microparticles is expected to have dissolved rapidly,
causing a rapid water uptake from the mucosal surface.
However, this high amount of water molecules interacting
with mannitol could have slowed down the dissolution of
RBV crystals, in a manner comparable with the well-known
poor solvent properties of syrups.
Cyclodextrins have been used for nasal drug delivery as
solubilizers, but also as penetration enhancers (Colombo
et al., 2016). In particular, the latter function has been evi-
denced for a-cyclodextrin (Merkus et al., 1999). Quite interest-
ingly the complexation of RBV with a-cyclodextrin via the
formation of an external intermolecular complex was demon-
strated (Grancher et al., 2005) and its antiviral activity in the
brain after intraperitoneal administration was evidenced pre-
viously (Jeulin et al., 2008, 2009). As a consequence, a-cyclo-
dextrin was attractive for the preparation of spray-dried
excipient microparticles for nasal delivery. Indeed, as far as ex
vivo permeation was concerned, the agglomerates containing
a-cyclodextrin and lecithin outperformed the others and
even provided a higher permeation than the micronized
powder. This could be related to a rapid RBV dissolution, to
the contribution to the concentration gradient of cyclodex-
trin complexed drug and to a direct effect on the nasal
mucosal tissue.
In addition, agglomerates showed excellent flow proper-
ties, as demonstrated by the calculated Compressibility Index,
and in preliminary experiments of insufflation with a device
suitable for animal nasal administration performed signifi-
cantly better than the micronized RBV and provided an
extensive distribution in the animal nasal cavity.
The study in animals showed that agglomerates contain-
ing a-cyclodextrin and lecithin determined higher brain RBV
concentrations compared with the micronized powder
administered as such, even if the values were not signifi-
cantly different (possibly as a consequence of the short time
set for the in vivo experiment and the single time point
acquired). Interestingly, the high RBV levels in both the pos-
terior cortex and cerebellum suggest an involvement of trige-
minal nerve pathway in the absorption of the antiviral drug
(Dhuria, 2010). However, it may be argued that the vascular
pathway (RBV absorption into the blood and BBB crossing)
contributed to the brain delivery, based on the reports on
the RBV complex with a-cyclodextrin enabling crossing the
BBB (Jeulin et al., 2009). For this reason, RBV levels previously
measured after intravenous administration of the same drug
dose per kg of body weight were directly compared with
those obtained here with the nasal agglomerates. The con-
centrations in the olfactory bulb were found not to be signifi-
cantly different. Considering that nasal bioavailability of
hydrophilic drugs is estimated lower than 10% (Casettari &
Illum, 2014) and that in most of studies the nasal dose
administered is 10-fold the injected one, the result is quite
promising in view of the nasal administration of this antiviral
drug, especially considering the possibility of repeating the
administration.
Very interestingly, when the olfactory bulb-to-plasma con-
centration ratios were calculated as a measure of the nose-
to-brain targeting efficiency (Serralheiro et al., 2015),
the brain targeting effect of the nasal administration was evi-
dent together with lower plasma concentrations, providing
the substantial possibility to reduce systemic side effects.
Conclusions
RBV was successfully formulated for nose-to-brain administra-
tion in the form of agglomerates with spray-dried excipient
microparticles suitable for efficient nasal deposition and able
to provide mucoadhesion and permeation enhancing proper-
ties. Despite being quite similar in their physico-chemical
properties, the agglomerates produced showed remarkable
differences with respect to permeation of the antiviral drug
across rabbit nasal mucosa. The differences were attributed
to the relative effect of the excipients in the microparticle
composition on the dissolution behavior of the drug. The
agglomerates containing a-cyclodextrin and lecithin micro-
particles enhanced the permeation compared to micronized
drug crystals. Results in vivo confirmed the potential of the
formulation for nose-to-brain delivery of the antiviral drug
with high brain targeting also in comparison with a conven-
tional intravenous administration.
The technological approach presented, i.e. the agglomer-
ation of excipient microparticles combined with the drug raw
material, has the potential to be a platform for the nose-to-
brain drug delivery of hydrophilic small molecules, but also
of peptides and proteins. In fact, it does not require the proc-
essing of the pharmacologically active substance, maximizing
its stability, and at the same time combines excipients useful
for biopharmaceutical events such as dissolution, mucoadhe-
sion and enhancement of the permeation through the nasal
epithelium, ultimately affecting drug bioavailability.
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